.png){kind=small}
Representing TLV Partners
September 2023
A hearty congratulations to TLV Partners for spearheading a successful $5.5 million seed capital raising for Scala Biodesign.
Scala Biodesign is pioneering a computational platform for protein engineering that seamlessly integrates physics-based models, artificial intelligence, and biological data analysis. This breakthrough technology empowers pharmaceutical companies to significantly cut costs and accelerate the development of protein-based products and processes.
Kudos to Roy Caner, head of EBN’s Hi-Tech department, and attorneys Oded Natan and Assaf Meltz for representing TLV Partners in this endeavor.
To read more, click here.
